Envista (NYSE:NVST) Announces Earnings Results, Beats Expectations By $0.07 EPS

Envista (NYSE:NVST) issued its quarterly earnings data on Wednesday. The company reported $0.41 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.34 by $0.07, FiscalAI reports. The company had revenue of $730.50 million for the quarter, compared to the consensus estimate of $716.11 million. Envista had a net margin of 2.41% and a return on equity of 7.11%. Envista’s revenue for the quarter was up 7.1% on a year-over-year basis. During the same period last year, the firm posted $0.26 EPS. Envista updated its FY 2026 guidance to 1.500-1.550 EPS.

Here are the key takeaways from Envista’s conference call:

• Strong second-quarter results: Envista delivered 5% core sales growth, 28% adjusted EBITDA growth, 58% adjusted EPS growth to $0.41, and 158% free-cash-flow conversion. Growth was broad-based across both reporting segments and major geographies.
• Full-year guidance was raised and narrowed to 3.5%-4.5% core growth, 11%-14% adjusted EBITDA growth, and adjusted EPS of $1.50-$1.55; the expected tax rate was also reduced to approximately 26% from prior guidance.
• Equipment & Consumables grew 8.5% organically, supported by high-single-digit growth in consumables and diagnostics, continued share gains, pricing, and new products. Spark again grew at a double-digit rate, while new implant, orthodontic, and consumable product launches are intended to support future growth.
• Operational execution continued to improve profitability, with adjusted EBITDA margin expanding 230 basis points to 14.7% through manufacturing productivity, G&A savings, pricing, and favorable volume mix. The company also repurchased approximately 2.4 million shares and ended the quarter with net debt of 0.7 times adjusted EBITDA.
• Management expects slower reported growth in the second half, including flat to slightly negative core growth in the fourth quarter because of four fewer selling days. China’s upcoming ortho and implant volume-based procurement programs are expected to create significant price pressure, including roughly 10%-15% implant price compression and potentially greater pressure in orthodontics.

Envista Stock Performance

NVST traded up $0.55 during trading on Wednesday, hitting $28.51. The stock had a trading volume of 6,998,014 shares, compared to its average volume of 2,798,520. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.06 and a current ratio of 2.44. The firm has a market capitalization of $4.64 billion, a P/E ratio of 69.54, a PEG ratio of 1.58 and a beta of 0.86. The company’s 50-day moving average price is $25.87 and its 200 day moving average price is $25.99. Envista has a twelve month low of $18.77 and a twelve month high of $30.42.

Institutional Trading of Envista

Several hedge funds have recently made changes to their positions in the company. Caitong International Asset Management Co. Ltd boosted its holdings in shares of Envista by 16,711.1% in the third quarter. Caitong International Asset Management Co. Ltd now owns 1,513 shares of the company’s stock valued at $31,000 after acquiring an additional 1,504 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Envista by 73.1% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 2,248 shares of the company’s stock worth $44,000 after acquiring an additional 949 shares during the period. UMB Bank n.a. raised its holdings in Envista by 46.1% during the fourth quarter. UMB Bank n.a. now owns 2,017 shares of the company’s stock worth $44,000 after purchasing an additional 636 shares in the last quarter. EverSource Wealth Advisors LLC raised its holdings in Envista by 378.0% during the second quarter. EverSource Wealth Advisors LLC now owns 2,414 shares of the company’s stock worth $47,000 after purchasing an additional 1,909 shares in the last quarter. Finally, Quarry LP purchased a new position in Envista during the third quarter worth about $66,000.

Wall Street Analyst Weigh In

NVST has been the subject of a number of research reports. Robert W. Baird upped their target price on shares of Envista from $30.00 to $31.00 and gave the company an “outperform” rating in a report on Thursday, May 7th. Weiss Ratings lowered Envista from a “hold (c)” rating to a “hold (c-)” rating in a report on Monday, May 11th. Piper Sandler boosted their price target on Envista from $25.00 to $26.00 and gave the company a “neutral” rating in a research report on Wednesday, July 29th. Evercore reaffirmed an “outperform” rating and set a $33.00 price objective on shares of Envista in a research note on Thursday, May 7th. Finally, Wall Street Zen cut Envista from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. Six investment analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $28.62.

Envista Company Profile

Envista Holdings Corporation is a global dental products company that develops, manufactures and markets a broad portfolio of dental consumables, equipment and technology solutions. Headquartered in Brea, California, Envista serves dental practitioners, specialists and laboratories in more than 150 countries. The company’s offerings span implant, orthodontic, endodontic and restorative product lines as well as digital imaging systems and practice management software.

Envista’s product brands include Nobel Biocare for dental implants and restorative solutions, Ormco for orthodontic appliances and treatment systems, Kerr for restorative and endodontic materials, KaVo for dental imaging and handpieces, and Vista for surgical drills and instruments.